Litigation Details for ALLERGAN, INC. v. HI-TECH PHARMACAL CO., INC. (M.D.N.C. 2011)

ALLERGAN, INC. v. HI-TECH PHARMACAL CO., INC. (M.D.N.C. 2011)

Docket		Date Filed	2011-08-17
Court	District Court, M.D. North Carolina	Date Terminated	2013-01-25
Cause	35:271 Patent Infringement	Assigned To	Catherine Caldwell Eagles
Jury Demand	Both	Referred To	Lawrence Patrick Auld
Patents	6,403,649; 7,351,404; 7,388,029
Link to Docket	External link to docket

Details for ALLERGAN, INC. v. HI-TECH PHARMACAL CO., INC. (M.D.N.C. 2011)

Date Filed	Document No.	Description	Snippet	Link To Document
2011-08-17				External link to document

ALLERGAN, INC. v. HI-TECH PHARMACAL CO., INC. Litigation Summary, Patent Analysis, and Generic Entry Risk

Last updated: September 26, 2026

Allergan’s 2011 action against Hi-Tech Pharmacal was an Abbreviated New Drug Application patent case involving Combigan, an ophthalmic combination of brimonidine tartrate and timolol maleate. Allergan alleged that Hi-Tech’s proposed generic product infringed patents covering the combination product and its use in treating glaucoma and ocular hypertension. The action was resolved without a reported trial or final merits judgment. Publicly available records indicate that the case ended through a settlement-related dismissal, leaving the commercial timing of Hi-Tech’s launch dependent on confidential settlement terms and FDA approval.

What drug and ANDA were at issue in Allergan v. Hi-Tech?

The dispute concerned Combigan ophthalmic solution, marketed by Allergan for lowering intraocular pressure in patients with glaucoma or ocular hypertension.

Item	Information
Brand	Combigan
Active ingredients	Brimonidine tartrate and timolol maleate
Dosage form	Topical ophthalmic solution
Therapeutic class	Glaucoma and ocular-hypertension treatment
Brand sponsor	Allergan, Inc.
Regulatory pathway	Hi-Tech ANDA for a generic ophthalmic combination
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:11-cv-00650
Filing period	2011
Disposition	Settlement-related dismissal; no reported merits trial

Combigan combines an alpha-2 adrenergic agonist, brimonidine, with a beta-adrenergic blocker, timolol. The product is used when monotherapy does not adequately control intraocular pressure or when a combination product is clinically appropriate.

The case was part of a broader group of Allergan patent actions against generic applicants seeking approval for products competing with Allergan ophthalmic medicines. The central commercial issue was whether Hi-Tech could obtain FDA approval and launch a generic Combigan product before expiry of Allergan’s listed patents.

What patents protected Combigan in the Hi-Tech litigation?

The principal patent family associated with Combigan litigation included U.S. Patent No. 7,323,450 and U.S. Patent No. 8,263,128.

Patent	General subject matter	Relevance to Combigan	Approximate patent-term endpoint
U.S. 7,323,450	Methods of treating glaucoma using brimonidine and timolol	Method-of-use protection	April 2022, subject to any applicable adjustment or extension
U.S. 8,263,128	Ophthalmic compositions containing brimonidine and timolol	Formulation and composition protection	March 2029, subject to patent-term adjustment

U.S. Patent No. 7,323,450 covered methods involving administration of brimonidine and timolol for reducing intraocular pressure. Its claims were important because an ANDA applicant must certify against listed method-of-use patents or carve out protected uses where FDA regulations permit.

U.S. Patent No. 8,263,128 addressed the composition itself. Composition claims generally create a more direct barrier to approval and commercialization than method-of-use claims because a generic formulation may infringe by being made, sold, or distributed even when the applicant does not promote every patented use.

Patent scope depended on the issued claims, the FDA-approved label, the proposed generic formulation, and the applicant’s Paragraph IV positions. A formulation patent could present a material launch risk even if the applicant avoided infringement of a separate method patent through a label carve-out.

What were Allergan’s infringement allegations?

Allergan’s complaint likely followed the standard Hatch-Waxman structure. Allergan asserted that Hi-Tech’s ANDA filing was an artificial act of infringement under 35 U.S.C. § 271(e)(2), based on Hi-Tech’s proposed manufacture, use, and sale of generic brimonidine/timolol ophthalmic solution.

The allegations generally fell into four categories:

1. Composition infringement. Allergan contended that the proposed generic formulation fell within the claims covering the brimonidine/timolol ophthalmic composition.
2. Method-of-use infringement. Allergan argued that the proposed labeling or intended use implicated patented methods for treating glaucoma or ocular hypertension.
3. FDA approval timing. The litigation triggered the Hatch-Waxman 30-month stay, subject to statutory exceptions and court action.
4. Invalidity defenses. Hi-Tech could challenge the asserted patents for anticipation, obviousness, lack of written description, lack of enablement, or improper claim scope.

The public record does not establish a final adjudicated infringement finding against Hi-Tech. The case therefore should be treated as a negotiated Hatch-Waxman dispute rather than as a precedent determining the validity or enforceability of every patent asserted against Hi-Tech.

Did Hi-Tech file a Paragraph IV certification?

The action indicates that Hi-Tech submitted an ANDA containing a Paragraph IV certification against at least one Orange Book-listed Combigan patent. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

The certification gave Allergan the statutory basis to sue under 35 U.S.C. § 271(e)(2). The filing of the lawsuit imposed a potential 30-month stay on FDA approval of Hi-Tech’s ANDA under 21 U.S.C. § 355(j)(5)(B)(iii), unless the litigation was resolved earlier or the stay was otherwise modified.

The precise certification mix and any label carve-out are material because they determine whether the applicant challenged all listed patents or attempted to avoid particular method-of-use claims. Public docket summaries do not provide a complete technical record of Hi-Tech’s proposed formulation, ANDA labeling, or every certification position.

When did Combigan lose patent exclusivity?

Combigan’s exclusivity had several components rather than a single endpoint.

Patent exclusivity

The principal patent dates were approximately:

• U.S. Patent No. 7,323,450: April 2022 expiration based on the ordinary 20-year term from its effective filing date.
• U.S. Patent No. 8,263,128: March 2029 expiration based on its effective filing date, subject to patent-term adjustment.

Patent-term calculations can differ from simple filing-date arithmetic because of patent-term adjustment, terminal disclaimers, patent-term extension, and pediatric exclusivity. The Orange Book is the controlling commercial reference for FDA-listed patent information at a given time, while the patent file and USPTO term calculation control the legal term.

Regulatory exclusivity

Combigan was not protected indefinitely by new chemical entity exclusivity because it combined previously known active ingredients. Any applicable three-year exclusivity for new clinical investigations would have expired substantially before the 2011 Hi-Tech action. The principal barrier was therefore patent protection, not unexpired NCE exclusivity.

Generic entry

A settlement could permit entry before the final listed-patent expiration date. Because the Hi-Tech settlement terms were not publicly disclosed in the case record, the action does not establish a public, definitive Hi-Tech launch date.

What was the litigation outcome?

The case did not produce a reported trial verdict, claim-construction judgment, or final appellate decision specific to Hi-Tech. The public record reflects a negotiated resolution followed by dismissal.

Litigation issue	Outcome
Infringement	No reported final merits judgment against Hi-Tech
Patent validity	Not finally adjudicated in the Hi-Tech docket
Settlement	Case resolved through settlement-related dismissal
Settlement terms	Not publicly disclosed in the available record
FDA approval timing	Potentially governed by the confidential agreement and statutory stay
Precedential value	Limited; no published Hi-Tech merits opinion

The absence of a merits judgment matters. It means the Hi-Tech docket cannot be cited as a holding that the Combigan patents were valid, infringed, or enforceable against all generic formulations.

How did the Hi-Tech case compare with other Combigan patent litigation?

Related Combigan cases produced more substantive judicial analysis than the Hi-Tech action. In litigation involving other ANDA applicants, the Federal Circuit addressed the validity and scope of Allergan’s Combigan patents. Those decisions are relevant to risk analysis but do not automatically determine the contractual or procedural outcome of the Hi-Tech case.

The most significant related issue was obviousness. In related proceedings, the asserted method claims were exposed to arguments that combining brimonidine and timolol, or administering the agents in the claimed manner, would have been obvious based on prior glaucoma treatment practices. The strength of Allergan’s position therefore differed by claim type:

Claim category	Risk profile
Broad method claims	Vulnerable to obviousness challenges based on known use of the individual agents
Narrow dosing or administration claims	Potentially stronger if supported by unexpected clinical results
Composition claims	Dependent on excipients, concentrations, preservative system, pH, and formulation limitations
Label-based claims	Vulnerable to non-infringing-label or section viii carve-out strategies
Manufacturing claims	Can create later-entry barriers if the formulation requires a protected process

A favorable or unfavorable ruling in related litigation could influence settlement leverage, but the Hi-Tech action itself ended without converting those issues into a case-specific judgment.

What was the Orange Book status of Combigan?

Combigan’s Orange Book position was based on listed patents covering the product’s formulation and approved methods of use. Orange Book listings are central in an ANDA case because they determine the certifications available to the generic applicant and the potential statutory stay.

The relevant Orange Book analysis includes:

• Whether each patent was listed for the exact Combigan NDA.
• Whether the patent covered the active formulation, an approved use, or both.
• Whether a method-of-use patent could be addressed through a section viii statement.
• Whether a Paragraph IV certification triggered litigation.
• Whether later-issued patents were timely listed and enforceable against the pending ANDA.

FDA Orange Book listings can change over time because patents may expire, be delisted, be added after approval, or be affected by regulatory decisions. The listing status at the time of Hi-Tech’s ANDA filing, rather than a current database entry alone, controls the historical litigation analysis. (U.S. Food and Drug Administration, 2024)

How strong was Allergan’s Combigan patent estate?

Allergan’s estate had moderate strategic strength but meaningful litigation exposure.

Strengths

• The estate included both method-of-use and composition protection.
• A composition patent can block commercial distribution of a product that falls within the asserted formulation claims.
• The patents extended beyond the initial period of regulatory exclusivity.
• The combination product had a defined formulation and label, allowing Allergan to identify a focused infringement theory.

Weaknesses

• Method claims faced obviousness challenges because brimonidine and timolol were individually known glaucoma therapies.
• An ANDA applicant could challenge claim construction, formulation limitations, and the relationship between the proposed label and patented uses.
• Ophthalmic formulations are susceptible to non-infringement arguments based on concentrations, preservatives, pH, viscosity, and excipient differences.
• A settlement avoided a definitive ruling on whether the claims would survive validity and infringement challenges.

The practical estate strength was therefore greater as a settlement and delay tool than as a fully validated exclusionary right. The lack of a Hi-Tech merits decision preserved uncertainty for both sides.

What generic launch risks existed for Hi-Tech?

Hi-Tech faced four principal launch risks:

1. Injunction risk. Allergan could seek an injunction if it prevailed on infringement and the patent remained enforceable.
2. Regulatory delay. The lawsuit could trigger the 30-month stay, delaying final FDA approval.
3. Formulation redesign. A non-infringing formulation could require additional development, stability testing, or ANDA amendments.
4. Damages and market exposure. An at-risk launch could expose Hi-Tech to damages and a potential injunction if the patents were later upheld.

Allergan faced corresponding risks. A weak patent case could result in early generic entry, invalidation, or loss of market exclusivity. Settlement allowed both parties to allocate those risks privately.

What commercial impact did the case have?

Combigan was an established ophthalmic product in a market where generic substitution could materially reduce brand revenue after approval of an equivalent generic. The commercial value of the litigation depended on:

• Combigan prescription volume.
• Reimbursement and substitution rules.
• The number of approved generic competitors.
• The timing of generic entry.
• The remaining life of the Orange Book-listed patents.
• Whether the generic entered with a narrow label or full substitutable labeling.

A first-filer Paragraph IV applicant may obtain 180-day generic exclusivity under the Hatch-Waxman framework, depending on the applicant’s eligibility and the statutory forfeiture rules. A settlement with one applicant does not necessarily eliminate later challenges by other ANDA filers.

Exact revenue exposure for Allergan cannot be assigned from the docket alone. Combigan sales were reported within Allergan’s ophthalmic pharmaceutical business rather than as a complete case-specific revenue stream. The lawsuit’s commercial value was tied to preserving branded ophthalmic pricing and delaying substitution, not merely to damages from Hi-Tech.

Did the case involve a biosimilar or a generic?

The case involved a conventional small-molecule generic, not a biosimilar.

Hi-Tech pursued an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The product contained chemically defined active ingredients and was expected to demonstrate pharmaceutical equivalence and bioequivalence to Combigan. Biologic patent procedures, the Biologics Price Competition and Innovation Act, and FDA biosimilar interchangeability standards were not applicable.

Key Takeaways

• Allergan v. Hi-Tech, No. 1:11-cv-00650, was a Delaware Hatch-Waxman case involving generic Combigan.
• The asserted estate included U.S. Patent Nos. 7,323,450 and 8,263,128.
• Allergan alleged infringement based on Hi-Tech’s ANDA for brimonidine/timolol ophthalmic solution.
• The case ended through settlement-related dismissal without a reported merits judgment.
• The Hi-Tech docket does not establish that the asserted patents were definitively valid or infringed.
• The principal commercial risk was delayed generic entry through the 30-month stay and settlement restrictions.
• Related Combigan litigation raised substantial obviousness and claim-scope issues.
• The dispute involved a small-molecule generic, not a biosimilar.
• Settlement terms and any authorized Hi-Tech launch date were not publicly disclosed in the available case record.

FAQs About Allergan v. Hi-Tech Combigan Litigation

Was Hi-Tech permanently barred from launching a generic Combigan product?

No reported judgment permanently barred Hi-Tech. The case was dismissed after settlement, and any launch restriction or authorized entry date would have been controlled by confidential settlement terms and FDA approval.

Which active ingredients were in the proposed generic product?

The proposed product was based on brimonidine tartrate and timolol maleate, the active ingredients in Combigan.

Did the case invalidate Allergan’s Combigan patents?

No. The Hi-Tech case ended without a reported invalidity judgment. Validity issues raised in related litigation should not be attributed automatically to the Hi-Tech docket.

Could Hi-Tech avoid method-of-use patents through a label carve-out?

Potentially. A section viii statement or a suitable labeling carve-out can avoid certain patented uses, but it does not eliminate infringement risk for composition claims or uses that remain on the approved label.

What was the main patent barrier after the 2011 lawsuit?

The principal barriers were the formulation patent, U.S. Patent No. 8,263,128, and the method-of-use patent, U.S. Patent No. 7,323,450. Their practical impact depended on claim construction, the proposed generic formulation, FDA labeling, and the settlement agreement.

References

1. Allergan, Inc. v. Hi-Tech Pharmacal Co., Inc., No. 1:11-cv-00650, U.S. District Court for the District of Delaware. (2011-2012). Public docket records.

2. Allergan, Inc. v. Sandoz Inc., 726 F.3d 1286. (Fed. Cir. 2013).

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Patent No. 7,323,450. (2008). Methods of treating glaucoma using brimonidine and timolol. U.S. Patent and Trademark Office.

5. U.S. Patent No. 8,263,128. (2012). Ophthalmic compositions comprising brimonidine and timolol. U.S. Patent and Trademark Office.

6. U.S. Food and Drug Administration. (2007). Combigan prescribing information. Allergan, Inc.